Ligand to Report First Quarter 2026 Financial Results on May 7, 2026

Rhea-AI Summary

Ligand (Nasdaq: LGND) will report first quarter 2026 financial results on Thursday, May 7, 2026. A conference call will begin at 8:30 a.m. Eastern to discuss results and provide a business update. Live webcast and replay will be available via the company’s webcast link.

Dial-in details include U.S. local, toll-free and international numbers with Meeting ID 304603090.

News Market Reaction – LGND

+0.09%

+0.09% Session close to close

In the Apr 22 session, LGND gained 0.09%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for Ligand’s first quarter 2026 financial results, with a confe...

Analysis

This announcement sets the timetable for Ligand’s first quarter 2026 financial results, with a conference call on May 7, 2026 at 8:30 a.m. ET. It follows the company’s practice of pre-announcing earnings dates and providing webcast access details. In context of prior earnings-related communications and recent regulatory filings, investors may focus on the upcoming call for updated revenue trends, royalty performance, and any changes to guidance or portfolio strategy.

Key Figures

Earnings date: May 7, 2026 Conference time: 8:30 a.m. Eastern time US local dial-in: +1 (585) 542-9983 +2 more

5 metrics

Earnings date May 7, 2026 Scheduled first quarter 2026 financial results release

Conference time 8:30 a.m. Eastern time Start time for Q1 2026 results conference call

US local dial-in +1 (585) 542-9983 United States local conference call number

US toll-free dial-in +1 (833) 461-5787 United States toll-free conference call number

Meeting ID 304603090 Conference call meeting ID for Q1 2026 results

Previous Earnings date Reports

1 past event · Latest: Feb 12 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 12	Earnings date notice	Neutral	-2.3%	Announced timing and access details for Q4 and full-year 2025 results call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The last earnings-date announcement coincided with a modest negative move of -2.32%, suggesting these scheduling headlines have previously aligned with mild downside.

Recent Company History

Recent news for Ligand shows a mix of operational and financial milestones. An earlier earnings-date release on Feb 12, 2026 preceded the Q4 and full-year 2025 report and was followed by a -2.32% move. Subsequent events included strong 2025 financial results and a partner’s full FDA approval for FILSPARI. Today’s announcement continues the pattern of formally scheduling earnings calls and updates through structured conference calls and webcasts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update.

Conference Call and Webcast Information
Date:		Thursday, May 7, 2026
Time:		8:30 a.m. Eastern time
Conference Call:		United States (Local): +1 (585) 542-9983 United States (Toll-Free): +1 (833) 461-5787 International: Global Dial-in Numbers Meeting ID: 304603090
Webcast:		Live and replay webcasts of the call are available here.

About Ligand
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 100 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.

Contacts

Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761

Media:         
Kellie Walsh
media@ligand.com
(914) 315-6072

FAQ

When will Ligand (LGND) report first quarter 2026 results?

Ligand will report Q1 2026 results on Thursday, May 7, 2026. According to the company, the announcement will be accompanied by a conference call at 8:30 a.m. Eastern to discuss results and provide a general business update.

How can investors join the Ligand (LGND) Q1 2026 conference call?

Investors can join via listed dial-in numbers or the live webcast. According to the company, U.S. local, toll-free and international numbers are available and a live webcast plus replay will be accessible through the company’s webcast link.

What time is Ligand's (LGND) Q1 2026 conference call on May 7, 2026?

The conference call starts at 8:30 a.m. Eastern on May 7, 2026. According to the company, the call will cover the first quarter results and include a general business update for investors and analysts.

Will a replay or webcast be available for Ligand's (LGND) May 7, 2026 call?

Yes, a live webcast and replay will be available following the call. According to the company, both live and replay webcasts of the conference call will be posted via the company’s webcast link for later listening.

What topics will Ligand (LGND) cover during the May 7, 2026 earnings call?

The call will discuss first quarter 2026 financial results and provide a general business update. According to the company, management will review results, business developments and answer questions from investors and analysts during the conference call.